Chemopreventive effect of dietary glutamine on colitis-associated colon tumorigenesis in mice

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1593-1600

  Tian, Yun ^a   Wang, Keming ^a   Wang, Zhaoxia ^a   Li, Nan ^b   Ji, Guozhong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; GLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLITIS; COLON CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; AZOXYMETHANE; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; COLITIS; COLON; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DIETARY SUPPLEMENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTAMINE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; REAL-TIME POLYMERASE CHAIN REACTION; RECTUM; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 84880315292     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt088     Document Type: Article

References (53)

1. Weir, H.K. et al. (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst., 95, 1276-1299.
2. Mantovani, A. et al. (2008) Cancer-related inflammation. Nature, 454, 436-444.
3. Danese, S. et al. (2011) Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut, 60, 1609-1610.
4. Lakatos, L. et al. (2006) Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm. Bowel Dis., 12, 205-211.
5. Harpaz, N. et al. (1996) Colorectal cancer in idiopathic inflammatory bowel disease. Semin. Diagn. Pathol., 13, 339-357.
6. Höie, O. et al.; European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). (2007) Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut, 56, 497-503.
7. Popivanova, B.K. et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest., 118, 560-570.
8. Greten, F.R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
9. Wilmore, D.W. et al. (1998) Role of glutamine in immunologic responses. Nutrition, 14, 618-626.
10. Wilmore, D.W. (2001) The effect of glutamine supplementation in patients following elective surgery and accidental injury. J. Nutr., 131(9 Suppl), 2543S-9S; discussion 2550S.
11. Elia, M. et al. (1997) The use of glutamine in the treatment of gastrointestinal disorders in man. Nutrition, 13, 743-747.
12. Lin, M.T. et al. (2002) The effect of glutamine-supplemented total parenteral nutrition on nitrogen economy depends on severity of diseases in surgical patients. Clin. Nutr., 21, 213-218.
13. Ockenga, J. et al. (2005) Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur. J. Clin. Nutr., 59, 1302-1309.
14. Neilly, P.J. et al. (1995) Topical glutamine therapy in experimental inflammatory bowel disease. Clin. Nutr., 14, 283-287.
15. Shinozaki, M. et al. (1997) Excess glutamine exacerbates trinitrobenzenesulfonic acid-induced colitis in rats. Dis. Colon Rectum, 40, S59-S63.
16. Deger, C. et al. (2006) The effect of glutamine on pancreatic damage in TNBS-induced colitis. Dig. Dis. Sci., 51, 1841-1846.
17. Kaya, E. et al. (1999) L-glutamine enemas attenuate mucosal injury in experimental colitis. Dis. Colon Rectum, 42, 1209-1215.
18. Vicario, M. et al. (2007) Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J. Nutr., 137, 1931-1937.
19. Xue, H. et al. (2011) Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN. J. Parenter. Enteral Nutr., 35, 188-197.
20. Fillmann, H. et al. (2007) Glutamine inhibits over-expression of proinflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology, 236, 217-226.
21. Chu, C.C. et al. (2012) Pretreatment with alanyl-glutamine suppresses T-helper-cell-associated cytokine expression and reduces inflammatory responses in mice with acute DSS-induced colitis. J. Nutr. Biochem., 23, 1092-1099.
22. Coëffier, M. et al. (2010) Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm. Bowel Dis., 16, 518-524.
23. Becker, C. et al. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21, 491-501.
24. Tian, Y. et al. (2011) Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int. J. Colorectal Dis., 26, 13-22.
25. Suzuki, R. et al. (2006) Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis, 27, 162-169.
26. Gismondo, M.R. et al. (1998) Immunostimulating effect of oral glutamine. Dig. Dis. Sci., 43, 1752-1754.
27. Manhart, N. et al. (2001) Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer's patches in endotoxemic mice. Ann. Surg., 234, 92-97.
28. Walrand, S. et al. (2008) Functional impact of high protein intake on healthy elderly people. Am. J. Physiol. Endocrinol. Metab., 295, E921-E928.
29. Cooper, H.S. et al. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69, 238-249.
30. Nowak, J. et al. (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis, 28, 1991-1995.
31. Cooper, H.S. et al. (2000) Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis, 21, 757-768.
32. Soyturk, M. et al. (2012) Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J. Gastroenterol., 18, 6452-60; discussion p. 6459.
33. González-García, A. et al. (2010) Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis- associated cancer. Gastroenterology, 138, 1374-1383.
34. Shiraki, M. et al. (2004) IL-12 p40 prevents the development of chronic enterocolitis in IL-10-deficient mice. Lab. Invest., 84, 1491-1500.
35. Adachi, M. et al. (2006) Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut, 55, 1104-1113.
36. Melgar, S. et al. (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 288, G1328-G1338.
37. Langholz, E. et al. (1992) Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology, 103, 1444-1451.
38. Pikarsky, E. et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
39. Yan, Y. et al. (2009) Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE, 4, e6073.
40. Okayasu, I. et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694-702.
41. Evans, M.A. et al. (1992) Intestinal fuels: glutamine, short-chain fatty acids, and dietary fiber. J. Am. Diet. Assoc., 92, 1239-46, 1249.
42. Ameho, C.K. et al. (1997) Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut, 41, 487-493.
43. da Costa, M.A. et al. (2003) Oral glutamine and the healing of colonic anastomoses in rats. JPEN. J. Parenter. Enteral Nutr., 27, 182-185; discussion 185-186.
44. Thibault, R. et al. (2007) Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology, 133, 1916-1927.
45. Gardiner, K.R. et al. (1995) Efficacy of glutamine-enriched enteral nutrition in an experimental model of mucosal ulcerative colitis. Br. J. Surg., 82, 1278-1279.
46. dos Santos, R.G. et al. (2010) Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. JPEN. J. Parenter. Enteral Nutr., 34, 408-413.
47. Li, Q. et al. (2005) Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol., 26, 318-325.
48. Greenhough, A. et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30, 377-386.
49. Jaiswal, M. et al. (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol., 281, G626-G634.
50. Rao, C.V. et al. (1999) Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis, 20, 641-644.
51. Kretzmann, N.A. et al. (2008) Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm. Bowel Dis., 14, 1504-1513.
52. Lecleire, S. et al. (2008) Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J. Nutr., 138, 2481-2486.
53. Hubert-Buron, A. et al. (2006) Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J. Nutr., 136, 1461-1465.